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INTRODUCTION
The British Thoracic Society (BTS) pub-
lished the guideline ‘The use of non-invasive
ventilation in acute respiratory failure’ in
2002.1 This was in response to trials that had
demonstrated that non-invasive ventilation
(NIV) was an alternative to invasive mechan-
ical ventilation (IMV) in life-threatening
respiratory acidosis due to acute exacerba-
tions of chronic obstructive pulmonary
disease (AECOPD). It drew attention to evi-
dence that, when NIV was used in the less
severely unwell patient, it also limited pro-
gression to more severe respiratory failure.2
The trial also demonstrated the feasibility, of
delivering NIV on general medical or admis-
sion wards that had enhanced support and
when staff were provided with ongoing
training.
In subsequent years, NIV has been shown
to deliver better rather than equivalent out-
comes to invasive ventilation in AECOPD and
better evidence has accumulated for the use
of NIV in non-COPD disease in the interven-
ing years. Repeated national audits have,
however, raised concerns that expected
patient beneﬁt is not being delivered and
have pointed to a number of process deﬁcien-
cies.3–5 There is also the risk, in the absence
of justifying trial evidence, that the preferred
use of NIV in AECOPD might be extended to
all hypercapnic patients, irrespective of cir-
cumstance or underlying disease process.
That this is a real risk might be inferred from
the BTS audits where the indication for NIV
was not COPD in over 30% of cases.3 4
NIV development in the UK has been
largely outside the organisational ‘umbrella’
of critical care. This may have adversely
affected resource allocation and contributed
to a lack of integration in NIV and IMV
patient pathways. Other unintended conse-
quences might be a restriction on access to
invasive ventilation and delay in the develop-
ment of extended applications of NIV, such
as accelerating extubation and its use in the
management of post-extubation respiratory
failure, in intensive care units.6 Intensive
care specialists may have little experience of
the ability of domiciliary NIV to reverse
chronic cardio-respiratory failure and this
may lead to underestimating survival, particu-
larly in advanced neuromuscular disease
(NMD) or chest wall disease (CWD).
For these varied reasons, the need for up
to date guidance was acknowledged by BTS
and the Intensive Care Society (ICS). The
aim of the guideline is to draw attention to
the evidence of suboptimal care in acute
hypercapnic respiratory failure (AHRF) in
the UK, provide an overview of the evidence
supporting the use of invasive and NIV,
encourage better communication between
admitting clinicians and critical care services
and the creation of AHRF patient pathways
and improve resourcing, training, outcomes
and patient experience for all adults who
develop acute hypercapnic respiratory
failure.
Conventionally, a pH <7.35 and a
PCO2>6.5 kPa deﬁnes acute respiratory
failure and, when persisting after initial
medical therapy, have been used as threshold
values for considering the use of NIV. More
severe degrees of acidosis, such as pH <7.25,
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have been used as a threshold for considering provision
of IMV. AHRF results from an inability of the respiratory
pump, in concert with the lungs, to provide sufﬁcient
alveolar ventilation to maintain a normal arterial PCO2.
Coexistent hypoxaemia is usually mild and easily
corrected.
AHRF complicates around 20% of acute exacerbations
of COPD.2 7 It signals advanced disease, a high risk of
future hospitalisations and limited long-term prognosis.
The median survival following recovery from AHRF was
1 year in a large case series.7 Around 12% of hypercap-
nic COPD patients died during the index admission and
this increased to 33% if the respiratory acidosis devel-
oped after hospitalisation. In asthma, acute hypercapnia
also signals an increased risk of death and an increased
likelihood of future life-threatening attacks.8 The same
risks apply to AHRF complicating cystic ﬁbrosis and
bronchiectasis although this has not been formally
reported. In the neuromuscular and CWD, including
morbid obesity, respiratory pump failure is often insidi-
ous in its onset but AHRF may be acute and unexpected.
Acute on chronic ‘decompensated’ episodes of AHRF
are more common and normally indicate the future
need for domiciliary NIV.
The guideline is targetted at medical, nursing and
physiotherapy staff working in emergency receiving
rooms, medical assessment units, admission wards,
respiratory wards and in high dependency and critical
care units. The Guideline applies to adults and does not
cover the management of AHRF due to cardiac failure,
trauma or acute brain injury. It refers to domiciliary NIV
but does not aim to provide guidance on this. The use
of non-invasive ventilation is intentionally more exten-
sively covered than IMV because the evidence and the
clinical experience of NIV is more recent and because
the technical aspects of IMV are covered by standard
texts.
The guideline does not cover the management of
AHRF due to cardiac failure, trauma or acute brain
injury. The guideline refers to domiciliary NIV but does
not aim to provide guidance on this. The use of non-
invasive ventilation is more extensively covered than
IMV because the evidence and the clinical experience
in its use is more recent and because the technical
aspects concerning IMV are well covered by standard
texts.
Methodology
Clinical questions were gathered in the PICOT (Patient,
Intervention, Comparison, Outcome and Time) format
to deﬁne the scope of the guideline and inform the lit-
erature search. Systematic electronic database searches
were conducted in order to identify potentially relevant
studies for inclusion in the guideline. For each clinical
question the following databases were searched: Ovid
MEDLINE (including MEDLINE In-Process), Ovid
EMBASE, EMSCO CINAHL, Ovid PsycINFO and the
Cochrane Library (including the Cochrane Database of
Systematic Reviews, the Database of Abstracts of Reviews
of Effects and the Cochrane Central Register of
Controlled Trials). An initial search was carried out in
November 2010 using a combination of indexed and
free-text terms deﬁning the clinical questions that had
been agreed by the guideline group as important in for-
mulating guidelines in AHRF. It was limited to studies
after 1990, in adults, in journals published in English
and where at least an abstract was available. The
searches identiﬁed a total of 582 potential papers which
were subsequently supplemented by publications known
to members or resulting from additional searches under-
taken by the writing groups after 2010. The literature
search was run again for relevant publications between
2010 and 2013 in September 2013, yielding a further
308 potentially relevant references. Additional refer-
ences were subsequently included from personal
collections.
Appraisal was performed using the criteria stipulated
by the AGREE collaboration. Each paper was appraised
by at least two reviewers. The writing lead for each
section read the title and abstract of papers identiﬁed
and agreed with at least one member of each writing
group whether such a paper was deﬁnitely, possibly rele-
vant or not relevant to the section. The criteria used
were whether the paper addressed a clinical question,
whether the study method used was satisfactory and that
it was available in English. Full papers were obtained for
all relevant or possibly relevant abstracts. Two members
for each section independently appraised each paper
using the SIGN critical appraisal checklists. An evidence
level was assigned to each study using SIGN method-
ology (table 1) and recommendations formulated
according to this evidence base (table 2).
Table 1 SIGN levels of evidence
1++ High-quality meta-analyses, systematic reviews of
RCTs, or RCTs with a very low risk of bias.
1+ Well-conducted meta-analyses, systematic reviews,
or RCTs with a low risk of bias.
1− Meta-analyses, systematic reviews, or RCTs with a
high risk of bias.
2++ High-quality systematic reviews of case control or
cohort or studies High-quality case–control or cohort
studies with a very low risk of confounding or bias
and a high probability that the relationship is causal.
2+ Well-conducted case control or cohort studies with a
low risk of confounding or bias and a moderate
probability that the relationship is causal.
2− Case control or cohort studies with a high risk of
confounding or bias and a significant risk that the
relationship is not causal.
3 Non-analytic studies, for example, case reports,
case series.
4 Expert opinion.
RCT, randomised controlled trial.
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Recommendations were graded from A to D, using
the SIGN Grading System (table 2), as indicated by the
strength of the evidence as listed in the tables.
Important practical points that lack research evidence
were highlighted as ‘Good Practice Points’.
Good practice points
Recommended best practice based on the clinical
experience of the guideline development group.
Units
Intrathoracic pressure and pressures relating to mechan-
ical ventilation are presented as cm H2O. Arterial blood
gas tensions are presented as kPa.
Summary of recommendations and good practice points
A summary of recommendations and good practice
points from the full guideline document9 are included
below.
For the detailed review of evidence and the full bibli-
ography please refer to the full guideline and the infor-
mation available on the BTS website at: https://www.
brit-thoracic.org.uk/guidelines-and-quality-standards/
All ﬁgures 1–3 and table 3 and boxes 1–4 from the
full Guideline are reproduced for reference.
SUMMARY OF RECOMMENDATIONS
Principles of mechanical ventilation
Modes of mechanical ventilation
Recommendation
1. Pressure targeted ventilators are the devices of
choice for acute NIV (grade B).
Good practice points
▸ Pressure support and pressure control modes are
effective.
▸ Only ventilators designed speciﬁcally to deliver NIV
should be used.
Choice of interface for NIV
Recommendation
2. A full face mask should usually be the ﬁrst type of
interface used (grade D).
Good practice points
▸ A range of masks and sizes is required and staff
involved in delivering NIV need training in and
experience of using them.
▸ NIV circuits must allow adequate clearance of
exhaled air through an exhalation valve or an integral
exhalation port on the mask.
Indications for and contraindications to NIV in AHRF
Recommendation
3. The presence of adverse features increase the risk
of NIV failure and should prompt consideration of
placement in HDU/ICU (grade C) (see ﬁgure 1).
Good practice points
▸ Adverse features should not, on their own, lead to
withholding a trial of NIV.
▸ The presence of relative contra-indications necessi-
tates a higher level of supervision, consideration of
placement in HDU/ICU and an early appraisal of
whether to continue NIV or to convert to IMV.
Monitoring during NIV
Good practice points
▸ Oxygen saturation should be continuously monitored.
▸ Intermittent measurement of pCO2 and pH is
required.
▸ ECG monitoring is advised if the patient has a pulse
rate >120 bpm or if there is dysrhythmia or possible
cardiomyopathy.
Supplemental oxygen therapy with NIV
Recommendations
4. Oxygen enrichment should be adjusted to achieve
SaO2 88–92% in all causes of AHRF treated by NIV
(grade A).
5. Oxygen should be entrained as close to the patient
as possible (grade C).
Good practice points
▸ As gas exchange will improve with increased alveolar
ventilation, NIV settings should be optimised before
increasing the FiO2.
▸ The ﬂow rate of supplemental oxygen may need to
be increased when ventilatory pressure is increased to
maintain the same SaO2 target.
▸ Mask leak and delayed triggering may be caused by
oxygen ﬂow rates >4 L/min which risks promoting or
exacerbating patient-ventilator asynchrony. The
requirement for high ﬂow rates should prompt a
careful check for patient-ventilator asynchrony.
▸ A ventilator with an integral oxygen blender is recom-
mended if oxygen at 4 L/min fails to maintain SaO2
>88%.
Table 2 SIGN grades of recommendations
A At least one meta-analysis, systematic review, or RCT
rated as 1++, and directly applicable to the target
population; or
A body of evidence consisting principally of studies
rated as 1+, directly applicable to the target population,
and demonstrating overall consistency of results.
B A body of evidence including studies rated as 2++,
directly applicable to the target population, and
demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 1++ or 1+.
C A body of evidence including studies rated as 2+,
directly applicable to the target population and
demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 2++.
D Evidence level 3 or 4; or
Extrapolated evidence from studies rated as 2+.
RCT, randomised controlled trial.
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Humidification with NIV
Recommendation
6. Humidiﬁcation is not routinely required (grade D).
Good practice point
Heated humidiﬁcation should be considered if the
patient complains of mucosal dryness or if respiratory
secretions are thick and tenacious.
Bronchodilator therapy with NIV
Good practice points
▸ Nebulised drugs should normally be administered
during breaks from NIV.
▸ If the patient is dependent on NIV, bronchodilator
drugs can be given via a nebuliser inserted into the
ventilator tubing.
Sedation with NIV
Recommendations
7. Sedation should only be used with close monitoring
(grade D).
8. Infused sedative/anxiolytic drugs should only be
used in an HDU or ICU setting (grade D).
9. If intubation is not intended should NIV fail, then
sedation/anxiolysis is indicated for symptom control in
the distressed or agitated patient (grade D).
Good practice point
In the agitated/distressed and/or tachypneic individual
on NIV, intravenous morphine 2.5–5 mg (± benzodiazep-
ine) will provide symptom relief and may improve toler-
ance of NIV.
Figure 2 Guide to initial settings
and aims with IMV. IMV, invasive
mechanical ventilation.
Figure 1 Summary for providing acute non-invasive ventilation (NIV).
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NIV complications
Good practice points
▸ Minor complications are common but those of a
serious nature are rare. Patients should be frequently
assessed to identify potential complications of NIV.
▸ Care is needed to avoid overtightening of masks.
▸ Previous episodes of ventilator-associated pneumo-
thorax warrant consideration of admission to HDU/
ICU and use of NIV at lower than normal inspiratory
pressures.
▸ The development of a pneumothorax usually requires
intercostal drainage and review of whether to con-
tinue with NIV.
Sputum retention
Recommendations
10. In patients with NMD, mechanical insufﬂation
and exsufﬂation should be used, in addition
to standard physiotherapy techniques, when cough
is ineffective and there is sputum retention
(grade B).
11. Minitracheostomy may have a role in aiding secre-
tion clearance in cases of weak cough (NMD/CWD) or
excessive amounts (COPD, CF) (grade D).
Modes of IMV
Recommendations
12. Spontaneous breathing should be established as
soon as possible in all causes of AHRF (grade C).
13. Controlled IMV may need to be continued in
some patients due to severe airﬂow obstruction, weak
muscles leading to poor triggering or to correct chronic
hypercapnia (grade C).
Good practice point
In the obstructive diseases, controlled IMV should be
continued until airway resistance falls.
Figure 3 The three phases of patient management in AHRF.
Table 3 Technical issues: a guide for when NIV is failing
Problem Cause(s) Solution (s)
Ventilator cycling independently of
patient effort
Inspiratory trigger sensitivity is too high
Excessive mask leak
Adjust trigger
Reduce mask leak
Ventilator not triggering despite visible
patient effort
Excessive mask leak
Inspiratory trigger sensitivity is too low
Reduce mask leak
Adjust trigger
For NM patients consider switch to PCV
Inadequate chest expansion despite
apparent triggering
Inadequate Tidal volume Increase IPAP. In NM or chest wall
disease consider longer Ti
Chest/abdominal paradox Upper airway obstruction Avoid neck flexion
Increase EPAP
Premature expiratory effort by patient Excessive Ti or IPAP Adjust as necessary
NIV, non-invasive ventilation.
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Invasive ventilation strategy
Recommendations
14. During controlled ventilation, dynamic hyperinﬂa-
tion should be minimised by prolonging expiratory time
(I:E ratio 1:3 or greater) and setting a low frequency
(10–15 breaths per minute) (grade C) (see ﬁgure 2).
15. Permissive hypercapnia (aiming for pH 7.2–7.25)
may be required to avoid high airway pressures when
airﬂow obstruction is severe (grade D).
16. Carbonic anhydrase inhibitors should not be rou-
tinely used in AHRF (grade C).
Positive end expiratory pressure
Recommendation
17. Applied extrinsic positive end expiratory pressure
(ePEEP) should not normally exceed 12 cm (grade C).
Sedation in IMV
Recommendation
18. Sedation should be titrated to a speciﬁc level of
alertness (grade B).
Patient-ventilator asynchrony
Recommendations
19. Ventilator asynchrony should be considered in all
agitated patients (including NIV) (grade C).
20. As patients recover from AHRF, ventilator require-
ments change and ventilator settings should be reviewed
regularly (grade C).
The use and timing of a tracheostomy
Recommendations
21. Performing routine tracheostomy within 7 days of
initiating IMV is not recommended (grade A).
22. The need for and timing of a tracheostomy should
be individualised (grade D).
Good practice points
▸ In AHRF due to COPD, and in many patients with
NMD or obesity hypoventilation syndrome, NIV sup-
ported extubation should be employed in preference
to inserting a tracheostomy.
▸ In AHRF due to NMD, alongside discussion with the
patient and carers, the decision to perform tracheos-
tomy should be multidisciplinary and should involve
discussion with a home ventilation unit.
Management of hypercapnic respiratory failure
Prevention of AHRF in AECOPD
Recommendations
23. In AHRF due to AECOPD, controlled oxygen
therapy should be used to achieve target saturations of
88–92% (grade A).
Good practice point
Controlled oxygen therapy should be used to achieve a
target saturation of 88–92% in ALL causes of AHRF.
Box 1 Indications for invasive mechanical ventilation in
acute exacerbations of chronic obstructive pulmonary
disease
▸ Imminent respiratory arrest
▸ Severe respiratory distress
▸ Failure of or contraindications to non-invasive ventilation (NIV)
▸ Persisting pH <7.15 or deterioration in pH despite NIV
▸ Depressed consciousness (GCS <8)
Box 2 Risk factors for extubation failure following inva-
sive mechanical ventilation (IMV)
▸ Positive fluid balance
▸ Raised rapid shallow breathing index during SBT
▸ Pneumonia or pulmonary disease as the cause requiring IMV
▸ Increased age
▸ Prolonged duration of IMV
▸ Anaemia
▸ Increased severity of illness
▸ Low albumin
▸ Previous failed extubation
▸ Bulbar dysfunction
Box 3 Essential requirements for a non-invasive ventila-
tion (NIV) service
▸ Specifically identified area(s) for NIV treatment at level 2
equivalence.
▸ Staffing levels above that of a general medical ward with one
nurse for every 2 NIV cases (especially during the first 24 h of
treatment).
▸ Locally developed NIV protocols (based on published best
practice guides) uniformly applied across all areas
▸ A designated lead with a ‘core’ multidisciplinary group (physi-
cians, nurses, physiotherapists) co-ordinating hospital wide
NIV service provision and performance
▸ Access to expert support for NIV technical advice in and out
of hours
▸ Mechanisms for regular audit
▸ Regular staff educational updates and training module for new
staff
Box 4 Discharge checklist after an episode of AHRF
▸ Arrange early specialist review, pulmonary rehabilitation and
help with smoking cessation as indicated.
▸ Consider early home visit for example, outreach chronic
obstructive pulmonary disease team/community nurses
▸ Discuss future care planning with patient/family and inform
community services of the result of such discussion.
▸ Provide warning card/inform ambulance services re future
need for controlled oxygen therapy
▸ Consider referral to home non-invasive ventilation service for
example, neuromuscular disease cases or suspected sleep-
disordered breathing
▸ Review reasons/route of admission and consider methods to
improve if these were problematic
▸ Learn from any identified mistakes through multi professional
review.
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Role of NIV in AECOPD
Recommendations
24. For most patients with AECOPD, the initial man-
agement should be optimal medical therapy and target-
ing an oxygen saturation of 88–92% (grade A).
25. NIV should be started when pH <7.35 and pCO2
>6.5 kPa persist or develop despite optimal medical
therapy (grade A).
26. Severe acidosis alone does not preclude a trial of
NIV in an appropriate area with ready access to staff who
can perform safe endotracheal intubation (grade B).
27. The use of NIV should not delay escalation to IMV
when this is more appropriate (grade C).
28. The practice of NIV should be regularly audited to
maintain standards (grade C).
Starting NIV in COPD
Good practice points
▸ Arterial blood gas measurement is needed prior to
and following starting NIV.
▸ Chest radiography is recommended but should not
delay initiation of NIV in severe acidosis.
▸ Reversible causes for respiratory failure should be
sought and treated appropriately.
▸ At the start of treatment, an individualised patient
plan (involving the patient wherever possible) should
document agreed measures to be taken in the event
of NIV failure.
Prognostic features relating to use of NIV in COPD
Recommendations
29. Advanced age alone should not preclude a trial of
NIV (grade A).
30. Worsening physiological parameters, particularly
pH and respiratory rate, indicate the need to change the
management strategy. This includes clinical review,
change of interface, adjustment of ventilator settings
and considering proceeding to endotracheal intubation
(grade A).
Good practice point
If sleep-disordered breathing predates AHRF, or evi-
dence of it complicates an episode, the use of a con-
trolled mode of NIV overnight is recommended.
Duration of NIV in COPD
Recommendation
31. NIV can be discontinued when there has been
normalisation of pH and pCO2 and a general improve-
ment in the patients condition (grade B).
Good practice points
▸ Time on NIV should be maximised in the ﬁrst 24 h
depending on patient tolerance and/or
complications.
▸ NIV use during the day can be tapered in the follow-
ing 2–3 days, depending on pCO2 self-ventilating,
before being discontinued overnight.
Optimising NIV delivery and technical considerations
Good practice point
Before considering NIV to have failed, always check that
common technical issues have been addressed and venti-
lator settings are optimal (see table 3).
Indications for IMV in AECOPD
Recommendations
32. IMV should be considered if there is persistent or
deteriorating acidosis despite attempts to optimise deliv-
ery of NIV (grade A).
33. Intubation should be performed in respiratory
arrest or periarrest unless there is rapid recovery from
manual ventilation/provision of NIV (grade D).
34. Intubation is indicated in management of AHRF
when it is impossible to ﬁt/use a non-invasive interface
for example, severe facial deformity, ﬁxed upper airway
obstruction, facial burns (grade D).
35. Intubation is indicated where risk/beneﬁt analysis
by an experienced clinician favours a better outcome
with IMV than with NIV (grade D).
Outcome following NIV or IMV in AECOPD
Recommendations
36. Prognostic tools may be helpful to inform discus-
sion regarding prognosis and with regard to the appro-
priateness of IMV, but with the caveat that such tools are
poorly predictive for individual patient use (grade B).
37. Clinicians should be aware that they are likely to
underestimate survival in AECOPD treated by IMV
(grade B).
38. Clinicians should discuss management of possible
future episodes of AHRF with patients, following an
epsiode requiring ventilatory support, because there is a
high risk of recurrence (grade B).
Acute asthma
Recommendations
39. NIV should not be used in patients with acute
asthma exacerbations and AHRF (grade C).
40. Acute (or acute on chronic) episodes of hypercap-
nia may complicate chronic asthma. This condition
closely resembles COPD and should be managed as
such (grade D).
Non-CF bronchiectasis
Recommendations
41. In patients with non-CF bronchiectasis and AHRF,
controlled oxygen therapy should be used (grade D).
42. In patients with non-CF bronchiectasis, NIV should
be started in AHRF using the same criteria as in
AECOPD (grade B).
43. In patients with non-CF bronchiectasis, NIV should
usually be tried before resorting to IMV in those with
less severe physiological disturbance (grade C).
44. In non-CF bronchiectasis, the patient’s clinical con-
dition prior to the episode of AHRF, and the reason for
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the acute deterioration, should be evaluated and used to
inform the decision about providing IMV (grade C).
Good practice points
▸ In patients with non-CF bronchiectasis, the precipitat-
ing cause is important in determining short-term
prognosis.
▸ Health status prior to the episode of AHRF is an
important predictor of outcome.
Cystic fibrosis
Recommendations
45. In patients with CF, controlled oxygen therapy
should be used in AHRF (grade D).
46. In patients with CF, NIV is the treatment of choice
when ventilatory support is needed (C).
47. In patients with CF, specialised physiotherapy is
needed to aid sputum clearance (D).
48. In patients with CF, a minitracheostomy combined
with NIV may offer greater chance of survival than
resorting to IMV (D).
Restrictive lung diseases
NMD and CWD
Recommendations
49. Controlled oxygen therapy should be used in
patients with NMD or CWD and AHRF (grade D).
50. NIV should almost always be trialled in the acutely
unwell NMD or CWD patient with hypercapnia. Do not
wait for acidosis to develop (grade D).
51. In patients with NMD or CWD, NIV should be con-
sidered in acute illness when vital capacity (VC) is
known to be <1 L and RR >20 even if normocapnic
(grade D).
52. In patients with NMD or CWD, consider controlled
ventilation as triggering may be ineffective (grade D).
53. In NMD or CWD, unless escalation to IMV is not
desired by the patient, or is deemed to be inappropriate,
intubation should not be delayed if NIV is failing
(grade D).
Good practice points
▸ Individuals with NMD and CWD who present with
AHRF should not be denied acute NIV.
▸ NIV is the ventilation mode of choice because
patients with NMD or CWD tolerate it well and
because extubation from IMV may be difﬁcult.
▸ In patients with NMD or CWD, deterioration may be
rapid or sudden, making HDU/ICU placement for
therapy more appropriate.
▸ In patients with NMD or CWD, senior/experienced
input is needed in care planning and is essential if
differences in opinion exist or develop between
medical staff and patient representatives.
▸ In patients with NMD, it should be anticipated that
bulbar dysfunction and communication difﬁculties, if
present, will make NIV delivery difﬁcult and may
make it impossible.
▸ Discussion about NIV and IMV, and patients, wishes
with respect to cardiopulmonary resuscitation, should
occur as part of routine care of patients with NMD or
CWD.
▸ In patients with NMD or CWD, nocturnal NIV should
usually be continued following an episode of AHRF,
pending discussion with a home ventilation service.
NIV failure and discontinuing NIV following recovery in NMD
and CWD
Good practice points
▸ In patients with NMD or CWD, intolerance of the
mask and severe dyspnoea are less likely to cause NIV
failure. Bulbar dysfunction makes NIV failure more
likely.
▸ Deterioration in patients with NMD or CWD may be
very sudden. Difﬁculty achieving adequate oxygen-
ation or rapid desaturation during a break from NIV
are important warning signs.
▸ In patients with NMD or CWD, the presence of
bulbar dysfunction, more profound hypoxaemia or
rapid desaturation during NIV breaks, suggests that
placement in HDU/ICU is indicated.
IMV in NMD/CWD
Recommendations
54. In patients with NMD or CWD, senior staff should
be involved in decision-making, in conjunction with
home mechanical ventilation specialists, if experience is
limited, and especially when the appropriateness of IMV
is questioned (grade D).
55. Advance care planning, particularly around the
potential future use of IMV, is recommended in patients
with progressive NMD or CWD. This may best be sup-
ported by elective referral to a home ventilation service
(grade D).
IMV strategy in NMD and CWD
Good practice points
▸ Patients with NMD usually require lower levels of
pressure support.
▸ Patients with CWD usually require higher levels of
pressure support.
▸ PEEP in the range 5–10 is commonly required to
increase residual volume and reduce oxygen depend-
ency in both patient groups.
Obesity hypoventilation syndrome
Recommendations
56. Controlled oxygen therapy should be used in
patients with hypoventilation syndrome (OHS) and
AHRF (grade D).
57. In patients with OHS, NIV should be started in
AHRF using the same criteria as in AECOPD (grade B).
58. NIV is indicated in some hospitalised obese hyper-
capnic patients with day time somnolence, sleep-
disordered breathing and/or right heart failure in the
absence of acidosis (grade D).
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NIV settings and placement in OHS
Good practice points
▸ High inspiratory positive airway pressure (IPAP) and
expiratory positive airway pressure (EPAP) settings
are commonly required in patients with OHS (eg,
IPAP >30, EPAP >8).
▸ Volume control (or volume assured) modes of provid-
ing NIV may be more effective when high inﬂation
pressures are required.
NIV failure in OHS
Good practice points
▸ Fluid overload commonly contributes to ventilatory
failure in patients with OHS, and its degree is easily
underestimated.
▸ Forced diuresis may be useful.
▸ As the risk of NIV failure is greater, and intubation
may be more difﬁcult, placement in HDU/ICU for
NIV is recommended.
Discontinuing NIV in OHS
Good practice points
▸ NIV can be discontinued as in patients with
AECOPD.
▸ Many patients with AHRF secondary to OHS will
require long-term domiciliary support (CPAP or
NIV).
▸ Following an episode of AHRF referral to a home
ventilation service is recommended.
IMV strategy in OHS
Good practice points
▸ In patients with OHS, pressure controlled MV is
recommended initially.
▸ In patients with OHS, high PEEP settings may be
needed to recruit collapsed lung units and correct
hypoxaemia.
▸ In patients with OHS, a forced diuresis is often
indicated.
Weaning from IMV
Introduction
Recommendations
59. Treating the precipitant cause of AHRF, normalis-
ing pH, correcting chronic hypercapnia and addressing
ﬂuid overload should all occur before starting weaning
(grade D).
60. A brain natriuretic petide (BNP)-directed ﬂuid
management strategy should be considered in patients
with known left ventricular dysfunction (grade B).
Weaning methods
Recommendations
61. Assessment of the readiness for weaning should be
undertaken daily (grade C).
62. A switch from controlled to assisted IMV should be
made as soon as patient recovery allows (grade C).
63. IMV patients should have a documented weaning
plan (grade B).
Assessing readiness for discontinuation of mechanical
ventilation
Recommendation
64. A 30-min spontaneous breathing trial (SBT) should
be used to assess suitability for extubation (grade B).
65. Factors including upper airway patency, bulbar
function, sputum load and cough effectiveness should
be considered prior to attempted extubation (grade D).
Outcome following extubation
Recommendation
66. Care is needed to identify factors that increase the
risk of extubation failure so that additional support,
such as NIV or cough assist, can be provided (grade B).
Weaning protocols
Recommendations
67. Although an organised and systematic approach to
weaning is desirable, protocols should be used with
caution in patients with AHRF (grade B).
68. The use of computerised weaning cannot be
recommended in AHRF (grade D).
The use of NIV in the ICU
Planned NIV to speed weaning from IMV
Recommendation
69. NIV is recommended to aid weaning from IMV in
patients with AHRF secondary to COPD (grade B).
70. In other causes of AHRF, NIV may have a role in
shortening the duration of IMV when local expertise in
its use exists (and of cough assist when indicated) and
there are features present that indicate extubation is
likely to be successful (grade D).
NIV in high risk patients
Recommendation
71. Prophylactic use of NIV should be considered to
provide post extubation support in patients with identi-
ﬁed risk factors for extubation failure (grade B).
NIV as ‘rescue’ therapy postextubation
Recommendations
72. NIV should not be used routinely for unexpected
post-extubation respiratory failure (grade B).
73. In COPD, a trial of NIV may be justiﬁed for unex-
pected post-extubation respiratory failure where local
expertise exists (grade D).
Care planning and delivery of care
Appropriate care environments for the delivery of NIV
Recommendations
74. NIV services should operate under a single clinical
lead with formal working links with the ICU (grade D).
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75. The severity of AHRF, and evidence of other organ
dysfunction, should inﬂuence the choice of care envir-
onment (grade C).
76. NIV should take place in a clinical environment
with enhanced nursing and monitoring facilities that are
beyond that of a general medical ward (grade C).
77. Initial care plans should include robust arrange-
ments for escalation, anticipating that around 20% of
AHRF cases should be managed in a level 2 or 3 envir-
onment (grade C).
Good practice points
▸ A 2–4 bedded designated NIV unit (located within a
medical high dependency area or within a respiratory
ward with enhanced stafﬁng levels) provides a sound
basis for the provision of NIV in a DGH serving a
population of 250 000 and with an average prevalence
of COPD.
▸ Areas providing NIV should have a process for audit
and interdisciplinary communication.
Palliative care and advanced care planning
Recommendations
78. Clinicians delivering NIV or IMV should have
ready access to palliative medicine (grade D).
79. Multidisciplinary advance care planning should be
an integral part of the routine outpatient management
of progressive or advanced disease and care plans
should be reviewed on presentation during an episode
of AHRF (grade D).
80. The use of NIV may allow time to establish patient
preference with regard to escalation to IMV (grade D).
End of life care
Good practice points
▸ Although removal of the NIV mask may be agreed as
preferable, a digniﬁed and comfortable death is pos-
sible with it in place.
▸ Clinicians delivering NIV or IMV should have training
in end of life care and the support of palliative care
teams.
Novel therapies
Extracorporeal CO2 removal (ECCO2R)
Recommendations
81. If local expertise exists, ECCO2R might be
considered:
▸ If, despite attempts to optimise IMV using lung pro-
tective strategies, severe hypercapnic acidosis (pH
<7.15) persists (grade D).
▸ When ‘lung protective ventilation’ is needed but
hypercapnia is contraindicated for example, coexist-
ent brain injury (grade D).
▸ For IMV patients awaiting a lung transplant
(grade D).
Good practice point
ECCO2R is an experimental therapy and should only be
used by specialist intensive care teams trained in its use,
and where additional governance arrangements are in
place, or in the setting of a research trial.
Helium/oxygen ventilation
Recommendation
82. Heliox should not be used routinely in the man-
agement of AHRF (grade B).
CONCLUSION
A central theme of the guideline is to promote integra-
tion in the planning and delivery of NIV and IMV in
acute hypercapnic respiratory failure. Despite evidence
demonstrating the value of non-invasive ventilation, its
introduction into routine clinical practice has not deliv-
ered the expected patient beneﬁt and it is likely that
NIV provision has, inadvertently, reduced access to IMV
in AECOPD and the other causes of AHRF in the UK.
The widespread introduction of an adequately
resourced and integrated AHRF patient pathway in our
hospitals is strongly recommended. It is expected that
this will lead to improved clinical outcomes and patient
experience.
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